EP3105317

CELLECTIS
Application Number
EP15706399A
Filing Date
Feb 13, 2015
Status
Opposition Rejected
Feb 4, 2022
Grant Date
Sep 19, 2018
External Links
Slate, Register

Biblio Summary

The patent EP3105317B1 was granted on Sep 19, 2018 by Cellectis The patent is currently Opposition Rejected.

The table below shows 2 patent oppositions filed on the patent at EPO, listing each opposing company and filing date. Tracking these filings indicates that the applicant is active in this industry, while opposing companies may be signaling their own interest in competing within the same space. These disputes are essential for insights into competitor actions, patent strategy and emerging technological trends.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

JAMES POOLE LIMITEDJun 19, 2019ADMISSIBLE
SCHIWECK WEINZIERL KOCH PATENTANWALTE PARTNERSCHAFT MBBJun 19, 2019ADMISSIBLE

The table below shows the patents of Cellectis that have been opposed by other companies.

Patent NumberTitleGrant DateOpposition Count
EP2997141Cd19 Specific Chimeric Antigen Receptor And Uses ThereofOct 12, 20221
EP3116902Method For Generating T-Cells Compatible For Allogenic TransplantationJan 1, 20204
EP3189073Trophoblast Glycoprotein (5T4, Tpbg) Specific Chimeric Antigen Receptors For Cancer ImmunotherapyDec 25, 20191

Dossier Documents of the Patent

The documents dossier of the patent at EPO including all essential records in the patent's lifecycle, from filing to grant to oppositions.

  • Date

    Description

  • Get instant alerts for new documents